These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

220 related items for PubMed ID: 14585835

  • 1. Characterization of endostatin binding to heparin and heparan sulfate by surface plasmon resonance and molecular modeling: role of divalent cations.
    Ricard-Blum S, Féraud O, Lortat-Jacob H, Rencurosi A, Fukai N, Dkhissi F, Vittet D, Imberty A, Olsen BR, van der Rest M.
    J Biol Chem; 2004 Jan 23; 279(4):2927-36. PubMed ID: 14585835
    [Abstract] [Full Text] [Related]

  • 2. Structural basis and potential role of heparin/heparan sulfate binding to the angiogenesis inhibitor endostatin.
    Sasaki T, Larsson H, Kreuger J, Salmivirta M, Claesson-Welsh L, Lindahl U, Hohenester E, Timpl R.
    EMBO J; 1999 Nov 15; 18(22):6240-8. PubMed ID: 10562536
    [Abstract] [Full Text] [Related]

  • 3. Molecular interplay between endostatin, integrins, and heparan sulfate.
    Faye C, Moreau C, Chautard E, Jetne R, Fukai N, Ruggiero F, Humphries MJ, Olsen BR, Ricard-Blum S.
    J Biol Chem; 2009 Aug 14; 284(33):22029-22040. PubMed ID: 19502598
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Non-heparan sulfate-binding interactions of endostatin/collagen XVIII in murine development.
    Rychkova N, Stahl S, Gaetzner S, Felbor U.
    Dev Dyn; 2005 Feb 14; 232(2):399-407. PubMed ID: 15614762
    [Abstract] [Full Text] [Related]

  • 6. Endostatin binds to blood vessels in situ independent of heparan sulfate and does not compete for fibroblast growth factor-2 binding.
    Chang Z, Choon A, Friedl A.
    Am J Pathol; 1999 Jul 14; 155(1):71-6. PubMed ID: 10393839
    [Abstract] [Full Text] [Related]

  • 7. Endostatin's heparan sulfate-binding site is essential for inhibition of angiogenesis and enhances in situ binding to capillary-like structures in bone explants.
    Gaetzner S, Deckers MM, Stahl S, Löwik C, Olsen BR, Felbor U.
    Matrix Biol; 2005 Jan 14; 23(8):557-61. PubMed ID: 15694132
    [Abstract] [Full Text] [Related]

  • 8. The first draft of the endostatin interaction network.
    Faye C, Chautard E, Olsen BR, Ricard-Blum S.
    J Biol Chem; 2009 Aug 14; 284(33):22041-22047. PubMed ID: 19542224
    [Abstract] [Full Text] [Related]

  • 9. The morphogenic properties of oligomeric endostatin are dependent on cell surface heparan sulfate.
    Clamp A, Blackhall FH, Henrioud A, Jayson GC, Javaherian K, Esko J, Gallagher JT, Merry CL.
    J Biol Chem; 2006 May 26; 281(21):14813-22. PubMed ID: 16481316
    [Abstract] [Full Text] [Related]

  • 10. Endostatins derived from collagens XV and XVIII differ in structural and binding properties, tissue distribution and anti-angiogenic activity.
    Sasaki T, Larsson H, Tisi D, Claesson-Welsh L, Hohenester E, Timpl R.
    J Mol Biol; 2000 Sep 01; 301(5):1179-90. PubMed ID: 10966814
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Divalent cations and heparin/heparan sulfate cooperate to control assembly and activity of the fibroblast growth factor receptor complex.
    Kan M, Wang F, To B, Gabriel JL, McKeehan WL.
    J Biol Chem; 1996 Oct 18; 271(42):26143-8. PubMed ID: 8824259
    [Abstract] [Full Text] [Related]

  • 13. Endostatin competes with bFGF for binding to heparin-like glycosaminoglycans.
    Reis RC, Schuppan D, Barreto AC, Bauer M, Bork JP, Hassler G, Coelho-Sampaio T.
    Biochem Biophys Res Commun; 2005 Aug 05; 333(3):976-83. PubMed ID: 15985216
    [Abstract] [Full Text] [Related]

  • 14. Endostatin phenylalanines 31 and 34 define a receptor binding site.
    Stahl S, Gaetzner S, Mueller TD, Felbor U.
    Genes Cells; 2005 Sep 05; 10(9):929-39. PubMed ID: 16115201
    [Abstract] [Full Text] [Related]

  • 15. The minimal active domain of endostatin is a heparin-binding motif that mediates inhibition of tumor vascularization.
    Olsson AK, Johansson I, Akerud H, Einarsson B, Christofferson R, Sasaki T, Timpl R, Claesson-Welsh L.
    Cancer Res; 2004 Dec 15; 64(24):9012-7. PubMed ID: 15604266
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Interaction of lipoprotein lipase with heparin fragments and with heparan sulfate: stoichiometry, stabilization, and kinetics.
    Lookene A, Chevreuil O, Ostergaard P, Olivecrona G.
    Biochemistry; 1996 Sep 17; 35(37):12155-63. PubMed ID: 8810923
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Selective Binding of Endostatin Peptide 4 to Recombinant VEGF Receptor 3 In Vitro.
    Han KY, Chang M, Ying HY, Lee H, Huang YH, Chang JH, Azar DT.
    Protein Pept Lett; 2015 Sep 17; 22(11):1025-30. PubMed ID: 26343062
    [Abstract] [Full Text] [Related]

  • 20. Characterization of growth factor-binding structures in heparin/heparan sulfate using an octasaccharide library.
    Ashikari-Hada S, Habuchi H, Kariya Y, Itoh N, Reddi AH, Kimata K.
    J Biol Chem; 2004 Mar 26; 279(13):12346-54. PubMed ID: 14707131
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.